MX2023006899A - Mutaciones ortogonales para heterodimerización. - Google Patents
Mutaciones ortogonales para heterodimerización.Info
- Publication number
- MX2023006899A MX2023006899A MX2023006899A MX2023006899A MX2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A MX 2023006899 A MX2023006899 A MX 2023006899A
- Authority
- MX
- Mexico
- Prior art keywords
- heterodimerization
- orthogonal mutations
- domains
- mutations
- orthogonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063123915P | 2020-12-10 | 2020-12-10 | |
| PCT/US2021/062951 WO2022125986A1 (en) | 2020-12-10 | 2021-12-10 | Orthogonal mutations for heterodimerization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006899A true MX2023006899A (es) | 2023-09-04 |
Family
ID=81974005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006899A MX2023006899A (es) | 2020-12-10 | 2021-12-10 | Mutaciones ortogonales para heterodimerización. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12312418B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259194A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500354A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118612A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116867514A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021397322A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3207821A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303518A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006899A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022125986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013537416A (ja) * | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Fc領域を含むモノマーポリペプチド及び使用方法 |
| CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| EA032681B1 (ru) * | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| SG11201506451UA (en) * | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| JP6724023B2 (ja) * | 2015-02-09 | 2020-07-15 | リサーチ ディベロップメント ファウンデーション | 改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド |
| EP3511340B1 (en) * | 2016-08-10 | 2024-10-02 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| DK3529269T3 (da) * | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| IL274071B2 (en) * | 2017-10-30 | 2025-10-01 | Hoffmann La Roche | Method for generating in vivo multispecific antibodies from monospecific antibodies |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| PE20210320A1 (es) * | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| JP7812230B2 (ja) * | 2019-04-25 | 2026-02-09 | エフ. ホフマン-ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| MX2022010176A (es) * | 2020-02-20 | 2023-01-16 | Win Therapeutics Inc | Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso. |
-
2021
- 2021-12-10 MX MX2023006899A patent/MX2023006899A/es unknown
- 2021-12-10 AU AU2021397322A patent/AU2021397322A1/en active Pending
- 2021-12-10 JP JP2023535392A patent/JP2024500354A/ja active Pending
- 2021-12-10 IL IL303518A patent/IL303518A/en unknown
- 2021-12-10 WO PCT/US2021/062951 patent/WO2022125986A1/en not_active Ceased
- 2021-12-10 CN CN202180091688.7A patent/CN116867514A/zh active Pending
- 2021-12-10 US US17/548,375 patent/US12312418B2/en active Active
- 2021-12-10 KR KR1020237022864A patent/KR20230118612A/ko active Pending
- 2021-12-10 CA CA3207821A patent/CA3207821A1/en active Pending
- 2021-12-10 EP EP21904522.6A patent/EP4259194A4/en active Pending
-
2025
- 2025-04-25 US US19/190,527 patent/US20260078202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024500354A (ja) | 2024-01-09 |
| US12312418B2 (en) | 2025-05-27 |
| US20260078202A1 (en) | 2026-03-19 |
| CA3207821A1 (en) | 2022-06-16 |
| EP4259194A1 (en) | 2023-10-18 |
| IL303518A (en) | 2023-08-01 |
| US20220363782A1 (en) | 2022-11-17 |
| AU2021397322A1 (en) | 2023-07-06 |
| AU2021397322A9 (en) | 2024-06-20 |
| CN116867514A (zh) | 2023-10-10 |
| EP4259194A4 (en) | 2025-03-19 |
| WO2022125986A1 (en) | 2022-06-16 |
| KR20230118612A (ko) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| CL2020003127A1 (es) | Anticuerpos bispecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| CY1124358T1 (el) | Ευκολως απομονωμενα διειδικα αντισωματα με φυσικης ανοσοσφαιρινης μορφη | |
| CL2018002046A1 (es) | Constructos de anticuerpo biespecíficos que se ligan a células t. | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| PY1888702A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| MX2023002374A (es) | Anticuerpo biespecifico anti-calr-cd3 mutante escindido y composicion farmaceutica. | |
| IL305736A (en) | Heterodimeric antibodies that bind cd3 and cldn6 | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
| AR128031A1 (es) | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden | |
| PH12021550096A1 (en) | Compositions of fcrn antibodies and methods of use thereof | |
| MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
| MX2021002299A (es) | Anticuerpos de anti-cd33 y metodos para usarlos. | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| WO2020223392A3 (en) | Cancer associated antibody compositions and methods of use | |
| CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
| CO2024000024A2 (es) | Moléculas de unión a gpc3 | |
| JOP20250298A1 (ar) | تركيبات جسم مضاد لإنتيجرين α4β7 وطرق استخدامها |